Preclinical Hematology R&D Solutions

Online Inquiry

First Name *

Last Name *

Business Email *

Phone

Company/Institution

Job Title

Services of Interest *

When do you expect your project to start?

Project Description

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.

Genetic Hematological Disease Models

Inquiry

Ace Therapeutics offers specialized preclinical contract research services utilizing validated in vivo models for genetic hematological disorders. These models serve as essential tools for evaluating therapeutic efficacy, understanding disease mechanisms, and conducting pharmacological profiling during early-stage drug development. Our focus lies in providing biologically relevant platforms that mimic human pathological conditions to generate meaningful preclinical insights.

Why In Vivo Models Are Essential in Genetic Hematology Research

Genetic blood disorders, such as β-thalassemia, sickle cell disease (SCD), and Fanconi anemia, present complex disease mechanisms involving gene mutations, impaired erythropoiesis, and systemic complications. In vivo models replicate these phenotypes in an organismal context, offering unique advantages:

Allow investigation of systemic pathophysiological responses
Enable multi-organ toxicity and biodistribution analysis
Facilitate pharmacokinetic and pharmacodynamic (PK/PD) profiling
Support longitudinal disease progression and treatment evaluation

Validated Genetic Hematological Disease Models

Our portfolio includes well-characterized models that recapitulate human disease pathology. Each model undergoes multi-tier validation (genetic, phenotypic, functional) to ensure translational relevance.

Disease Model	Animal Strain	Applications
Sickle Cell Disease	Townes transgenic mice	Small-molecule and gene therapy evaluation; pain and inflammation studies
β-Thalassemia	Hbbth3/+ mouse model	Iron chelator testing; erythropoiesis-stimulating agents; gene editing
Fanconi Anemia	Fanca^−/−, Fancc^−/− mouse strains	DNA repair pathway modulators; bone marrow protection strategies
Diamond-Blackfan Anemia	Rps19^+/− mouse model	Erythropoiesis-targeting therapies; gene correction studies
Hereditary Spherocytosis	Ank1 mutant mice	Drug screening for hemolysis prevention; spleen-targeted therapies
α-Thalassemia	Hba1/Hba2^−/−	Gene editing, fetal Hb inducers
G6PD Deficiency	C3H/HeJ-G6pdxm1	Antioxidants, NADPH pathway modulators

Our Service Capabilities

We utilize established genetic models to conduct tailored studies, including

Core Preclinical Services

Study design and consultation
Therapeutic efficacy evaluation
Pharmacokinetics and biodistribution
Hematological and biochemical analysis
Histopathology and organ-level assessments
Molecular biomarker validation

Data Quality Assurance

Compliance with industry-standard protocols.
Statistical rigor (power analysis, blinded evaluations).
Integrated genomics/phenomics analysis.

Study Design Flexibility

Endpoint Customization: Tailored assessments (e.g., flow cytometry for HSC engraftment, MRI for organ damage).
Multi-Dosing Regimens: Acute/chronic dosing, combination therapy testing.
Biomarker Panels: Disease-specific markers (e.g., %HbF for SCD, ferritin for thalassemia).

Model Validation and Relevance

Each model undergoes rigorous validation based on genetic background, phenotypic fidelity, and translational relevance. Our validation approach includes:

Genotypic Confirmation: PCR and sequencing-based verification of transgene or knockout status.
Phenotypic Assessment: Routine hematology (CBC, reticulocyte count), organ histology, and clinical scoring.
Reproducibility Testing: Standardized protocols ensure consistent responses across cohorts and experimental repeats.
Drug Response History: Many of our models are referenced in peer-reviewed studies demonstrating their responsiveness to established or investigational agents.

Model Characteristics

SCD Models

Exhibit chronic hemolysis, vaso-occlusive crises, and multi-organ damage. Ideal for testing disease-modifying agents.

Beta-Thalassemia Models

Show ineffective erythropoiesis, anemia, and iron overload. Suited for therapies targeting globin chain imbalance.

Hemophilia Models

Display prolonged bleeding and spontaneous hemorrhage. Optimal for hemostatic agents and gene therapies.

Fanconi Anemia Models

Feature bone marrow failure and cancer predisposition. Used for DNA damage response therapeutics.

Applications of Our Services

Our in vivo modeling services are suitable for:

Lead optimization and candidate selection
Mechanism-of-action studies
Dose-range finding and safety profiling
Biomarker identification and validation
Proof-of-concept efficacy demonstration

Whether you are exploring early proof-of-concept or need robust in vivo data to guide clinical candidate selection, Ace Therapeutics is your trusted preclinical CRO partner. Contact us today to learn more about our genetic hematological disease modeling capabilities.

Frequently Asked Questions About Genetic Hematological Disease Models

What distinguishes your SCD models from standard transgenic lines

Our Townes model expresses humanized HbS, recapitulating human pathophysiology. Validation includes quantifiable sickling, chronic inflammation, and organ damage.

Can you support studies for rare diseases like Diamond-Blackfan Anemia

Yes. We adapt models like Rps19+/- mice and validate them via ribosomal profiling and erythroid progenitor assays.

How are models validated for drug testing

Three-tiered approach: Genetic (PCR/Western blot), Phenotypic (hematology, histopathology), Functional (disease-specific challenges e.g., hypoxia for SCD).

How is quality ensured during experiments?

We follow standardized protocols, include appropriate controls, and conduct regular audits to ensure data quality and reliability.

What endpoints suit gene therapy studies

Durability (vector persistence), efficacy (phenotype rescue), and safety (off-target edits, immunogenicity).